The oncology field is undergoing a profound transformation as it seeks to enhance patient care, streamline clinical trials, and accelerate drug development. Traditional approaches often face challenges in efficiency and integration, creating barriers to optimal cancer care and research. Flatiron Health has emerged as a leader, revolutionizing the landscape with its innovative technology and comprehensive real-world data solutions.
Flatiron Health transforms clinical trials with advanced technology, optimizing protocols, patient identification, and site selection. Utilizing over 3.5 million patient records, its services have increased Black patient eligibility by 47% in a Phase III myeloma trial and identified diverse populations for breast cancer studies.
Flatiron Clinical Pipe™ enhances data transfer between EHR and EDC systems, serving 35 sponsors and connected to 85 sites, improving efficiency and supporting various indications. OncoTrials® streamlines recruitment using EHR data to match, screen, and track patients, reducing site burdens with real-time notifications.
Flatiron Health excels in low-interventional study design and evidence generation, addressing clinical trial diversity with solutions that meet FDA standards. Its technology accelerates research, improves trial diversity, and enhances patient outcomes, positioning Flatiron as a leader in oncology research.
Flatiron Horizon is central to these solutions, integrating extensive oncology data, proprietary curation methods, disease-specific machine learning models, and deep oncology expertise. This platform enables rapid and accurate data curation, turning patient data into actionable evidence. Supported by over 4 million de-identified patient records and 1.5 billion data points, Flatiron Health has contributed to more than 1,500 clinical trials across four global cancer site networks. With over five years of collaboration with the FDA and NICE, Flatiron Health is a leader in evidence solutions.
By harnessing every patient’s cancer journey, we transform care and research, driving innovation and ensuring a future where technology and science continuously advance the quality of life for all. — Carolyn Starrett, CEO
Flatiron’s oncology evidence solutions cover every phase of the biopharma lifecycle, including hypothesis generation, unmet needs identification, target product profile design, launch planning, and commercial assessments. It aids clinical study design by understanding the disease’s natural history, constructing hybrid control arms, and executing representative trials. For diversity planning, it optimizes inclusion/exclusion criteria and assesses treatment patterns among underrepresented groups.
Medical affairs services support peri-launch evidence generation and scientific literature development. Regulatory submissions benefit from analyses of disease burden, external control arms, and real-world data. Post-marketing commitments are addressed through safety, efficacy, and long-term effectiveness assessments, while label expansion focuses on clinical effectiveness and dosing optimization. Commercial strategy services include launch planning, utilization assessments, and pricing forecasts, with safety and pharmacoepidemiology services evaluating safety signals and adverse events.
Flatiron Health’s unmatched real-world data capabilities include over 4 million patient journeys, 22+ tumor types, and multimodal data from major oncology markets worldwide. This extensive data supports product profile refinement, effectiveness studies, and regulatory and HTA submissions. Its prospective evidence generation uses advanced technology to design and execute observational studies, ensuring effective trial protocols, site matching, and patient identification. In point-of-care solutions, Flatiron enhances patient care and practice efficiency. OncoEMR® streamlines electronic health record management, while Flatiron Assist™ integrates treatment options and trial information into daily workflows.
Flatiron Health also supports value-based care with solutions for Episode of Care Management (EOM) and Merit-based Incentive Payment System (MIPS), and the OncoAir™ app enables on-the-go patient care management. Its oncology EMR software and decision support tools, designed for community oncology and hospitals, focus on evidence-based medicine, innovative treatments, and integrating clinical research.
Flatiron Health is transforming cancer care with innovative technology and real-world evidence. By seamlessly integrating clinical research and patient care, the company advances oncology outcomes and supports global partnerships. It continues to drive progress and make every patient story count.